Altria sought authorization under an FDA pilot program, while regulatory risk tied to FDA statements is under scrutiny.
3 reports, 2 independent
Updated Sep 2
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Altria sought authorization under an FDA pilot program, while regulatory risk tied to FDA statements is under scrutiny.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Altria sued the FDA over its product review process and engaged in lobbying targeting Donald Trump.1 source
Altria applied to the FDA pilot program for authorization.1 source
Keep exploring
The entities involved
Related events
- The FDA is facing public scrutiny due to oversight failures, leading to the introduction of new legislation targeting agency shortcomings.
- The FDA is accused of failing to enforce safety regulations and operating under current rules without in-person oversight.
- The FDA has issued a Major Amendment regarding AxoGen's submission on August 25, 2025.
- Anavex Life Sciences submitted data for FDA discussions and received scientific advice from the EMA.
- FDA approval enables commercial opportunity involving CBRE Group.